Fasciculoventricular Pathways Responsible for Ventricular Preexcitation in Patients with Danon Disease
Yang Liu,Feng Wang,Xin Chen,Yingcong Liang,Hai Deng,Hongtao Liao,Fang Rao,Wei,Qianhuan Zhang,Bin Zhang,Xianzhang Zhan,Xianhong Fang,Sandeep Nair,Michael Shehata,Xunzhang Wang,Yumei Xue,Shulin Wu
DOI: https://doi.org/10.1161/circep.118.006704
2018-01-01
Abstract:HomeCirculation: Arrhythmia and ElectrophysiologyVol. 11, No. 9Fasciculoventricular Pathways Responsible for Ventricular Preexcitation in Patients With Danon Disease Free AccessLetterPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissionsDownload Articles + Supplements ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toSupplementary MaterialsFree AccessLetterPDF/EPUBFasciculoventricular Pathways Responsible for Ventricular Preexcitation in Patients With Danon Disease Yang Liu, MD, PhD, Feng Wang, MD, Xin Chen, MD, Yingcong Liang, MD, Hai Deng, MD, Hongtao Liao, MD, Fang Rao, MD, PhD, Wei Wei, MD, Qianhuan Zhang, MD, Bin Zhang, MD, Xianzhang Zhan, MD, Xianhong Fang, MD, Sandeep Nair, MD, Michael Shehata, MD, Xunzhang Wang, MD, Yumei Xue, MD and Shulin Wu, MD Yang LiuYang Liu Guangdong Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China (Y.L., F.W., X.C., Y.L., H.D., H.L., F.R., W.W., Q.Z., B.Z., X.Z., X.F., Y.X., S.W.) Guangdong Provincial Key Laboratory of Clinical Pharmacology, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China (Y.L., F..W., X.C., H.D., H.L., F.R., W.W., Q.Z., B.Z., X.Z., X.F., Y.X., S.W.) Heart Institute, Cedars Sinai Medical Center, Los Angeles, CA (Y.L., S.N., M.S., X.W.). , Feng WangFeng Wang Guangdong Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China (Y.L., F.W., X.C., Y.L., H.D., H.L., F.R., W.W., Q.Z., B.Z., X.Z., X.F., Y.X., S.W.) Guangdong Provincial Key Laboratory of Clinical Pharmacology, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China (Y.L., F..W., X.C., H.D., H.L., F.R., W.W., Q.Z., B.Z., X.Z., X.F., Y.X., S.W.) , Xin ChenXin Chen Guangdong Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China (Y.L., F.W., X.C., Y.L., H.D., H.L., F.R., W.W., Q.Z., B.Z., X.Z., X.F., Y.X., S.W.) Guangdong Provincial Key Laboratory of Clinical Pharmacology, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China (Y.L., F..W., X.C., H.D., H.L., F.R., W.W., Q.Z., B.Z., X.Z., X.F., Y.X., S.W.) , Yingcong LiangYingcong Liang Guangdong Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China (Y.L., F.W., X.C., Y.L., H.D., H.L., F.R., W.W., Q.Z., B.Z., X.Z., X.F., Y.X., S.W.) , Hai DengHai Deng Guangdong Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China (Y.L., F.W., X.C., Y.L., H.D., H.L., F.R., W.W., Q.Z., B.Z., X.Z., X.F., Y.X., S.W.) Guangdong Provincial Key Laboratory of Clinical Pharmacology, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China (Y.L., F..W., X.C., H.D., H.L., F.R., W.W., Q.Z., B.Z., X.Z., X.F., Y.X., S.W.) , Hongtao LiaoHongtao Liao Guangdong Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China (Y.L., F.W., X.C., Y.L., H.D., H.L., F.R., W.W., Q.Z., B.Z., X.Z., X.F., Y.X., S.W.) Guangdong Provincial Key Laboratory of Clinical Pharmacology, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China (Y.L., F..W., X.C., H.D., H.L., F.R., W.W., Q.Z., B.Z., X.Z., X.F., Y.X., S.W.) , Fang RaoFang Rao Guangdong Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China (Y.L., F.W., X.C., Y.L., H.D., H.L., F.R., W.W., Q.Z., B.Z., X.Z., X.F., Y.X., S.W.) Guangdong Provincial Key Laboratory of Clinical Pharmacology, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China (Y.L., F..W., X.C., H.D., H.L., F.R., W.W., Q.Z., B.Z., X.Z., X.F., Y.X., S.W.) , Wei WeiWei Wei Guangdong Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China (Y.L., F.W., X.C., Y.L., H.D., H.L., F.R., W.W., Q.Z., B.Z., X.Z., X.F., Y.X., S.W.) Guangdong Provincial Key Laboratory of Clinical Pharmacology, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China (Y.L., F..W., X.C., H.D., H.L., F.R., W.W., Q.Z., B.Z., X.Z., X.F., Y.X., S.W.) , Qianhuan ZhangQianhuan Zhang Guangdong Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China (Y.L., F.W., X.C., Y.L., H.D., H.L., F.R., W.W., Q.Z., B.Z., X.Z., X.F., Y.X., S.W.) Guangdong Provincial Key Laboratory of Clinical Pharmacology, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China (Y.L., F..W., X.C., H.D., H.L., F.R., W.W., Q.Z., B.Z., X.Z., X.F., Y.X., S.W.) , Bin ZhangBin Zhang Guangdong Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China (Y.L., F.W., X.C., Y.L., H.D., H.L., F.R., W.W., Q.Z., B.Z., X.Z., X.F., Y.X., S.W.) Guangdong Provincial Key Laboratory of Clinical Pharmacology, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China (Y.L., F..W., X.C., H.D., H.L., F.R., W.W., Q.Z., B.Z., X.Z., X.F., Y.X., S.W.) , Xianzhang ZhanXianzhang Zhan Guangdong Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China (Y.L., F.W., X.C., Y.L., H.D., H.L., F.R., W.W., Q.Z., B.Z., X.Z., X.F., Y.X., S.W.) Guangdong Provincial Key Laboratory of Clinical Pharmacology, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China (Y.L., F..W., X.C., H.D., H.L., F.R., W.W., Q.Z., B.Z., X.Z., X.F., Y.X., S.W.) , Xianhong FangXianhong Fang Guangdong Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China (Y.L., F.W., X.C., Y.L., H.D., H.L., F.R., W.W., Q.Z., B.Z., X.Z., X.F., Y.X., S.W.) Guangdong Provincial Key Laboratory of Clinical Pharmacology, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China (Y.L., F..W., X.C., H.D., H.L., F.R., W.W., Q.Z., B.Z., X.Z., X.F., Y.X., S.W.) , Sandeep NairSandeep Nair Heart Institute, Cedars Sinai Medical Center, Los Angeles, CA (Y.L., S.N., M.S., X.W.). , Michael ShehataMichael Shehata Heart Institute, Cedars Sinai Medical Center, Los Angeles, CA (Y.L., S.N., M.S., X.W.). , Xunzhang WangXunzhang Wang Heart Institute, Cedars Sinai Medical Center, Los Angeles, CA (Y.L., S.N., M.S., X.W.). , Yumei XueYumei Xue Guangdong Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China (Y.L., F.W., X.C., Y.L., H.D., H.L., F.R., W.W., Q.Z., B.Z., X.Z., X.F., Y.X., S.W.) Guangdong Provincial Key Laboratory of Clinical Pharmacology, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China (Y.L., F..W., X.C., H.D., H.L., F.R., W.W., Q.Z., B.Z., X.Z., X.F., Y.X., S.W.) and Shulin WuShulin Wu Shulin Wu, MD, Guangdong Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, 106 Zhongshan Er Rd, Guangzhou 510080, China. Email E-mail Address: [email protected] Guangdong Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China (Y.L., F.W., X.C., Y.L., H.D., H.L., F.R., W.W., Q.Z., B.Z., X.Z., X.F., Y.X., S.W.) Guangdong Provincial Key Laboratory of Clinical Pharmacology, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China (Y.L., F..W., X.C., H.D., H.L., F.R., W.W., Q.Z., B.Z., X.Z., X.F., Y.X., S.W.) Originally published13 Sep 2018https://doi.org/10.1161/CIRCEP.118.006704Circulation: Arrhythmia and Electrophysiology. 2018;11:e006704Danon disease, caused by the mutations in the gene of LAMP2(lysosome-associated membrane protein 2), is an X-linked dominant disorder classically characterized by the triad of cardiomyopathy, skeletal myopathy, and mental retardation.1,2 Cardiomyopathy typically manifests a hypertrophic phenotype; ventricular preexcitation is the most frequently encountered ECG abnormality in such patients and occurs in 68.2% of men and 26.7% of women.3 The pathological hallmark of Danon disease is intracytoplasmic vacuole accumulation containing glycogen granules and autophagic materials which lead to cardiac hypertrophy,1 but the underlying mechanism responsible for ventricular preexcitation continues to be a perplexing conundrum. The objective of this study was to determine the mechanism of ventricular preexcitation in patients with Danon disease.We enrolled 197 patients with unexplained left ventricular hypertrophy, and ventricular preexcitation was present in 10 (10 of 197; 5%) unrelated patients in whom genetic testing identified 3 (3 of 10; 30%) Danon disease patients with different LAMP2 mutations. Of the 3 patients, all were men aged 17 to 23 years at diagnosis, and electrophysiological study was performed in 2 patients.Intracardiac recordings in patient 1 demonstrated a slightly short His-ventricular (HV) interval of 30 ms, and local ventricular activation recorded at the His bundle area significantly earlier than the right ventricular apex during sinus rhythm (see the first beat in the Figure [A]). During ventricular overdrive stimulation, ventriculoatrial (VA) conduction was decremental and concentric with the earliest atrial retrograde activation at the His bundle, and the activation sequence of His bundle and right bundle (RB) was noted to be similar to sinus activation with H-RB sequence (Figure [A]). The deflections of the RB electrogram during sinus rhythm and ventricular pacing were −/+ and +/−, respectively; the deflection of the His bundle electrogram was −/+/− during both sinus rhythm and ventricular pacing, suggesting that the His activation during ventricular pacing was orthodromic, while the RB potential was activated retrograde. Atrial programmed stimulation resulted in prolongation of the atrio-His (AH) and atrioventricular (AV) intervals without changing QRS morphologies and HV intervals (Figure [B]), thereby excluding the presence of antegrade conduction over an accessory pathway connecting the atrium to the ventricle. These findings favor the diagnosis of a fasciculoventricular (FV) pathway with bidirectional conduction which takes off from the proximal part of the His bundle, bypasses conduction over the distal portion of the His bundle, the bundle branches, and Purkinje system and hence, is responsible for ventricular preexcitation and early local ventricular activation at the His bundle region during sinus rhythm, as well as the H-RB activation sequence during ventricular pacing (Figure [C] and [D]).Download figureDownload PowerPointFigure. Electrophysiological characteristics and schematic diagrams of fasciculoventricular pathways. A, Tracings obtained from electrophysiological study in patient 1. Midventricular pacing demonstrates decremental and concentric VA conduction with Wenckebach block phenomenon (a long-dotted line used as reference). Note that the earliest ventricular depolarization is seen on the His recording during sinus rhythm (a long-dotted line used as reference), and the His deflections precede the right bundle deflections during midventricular pacing (short-dotted lines used as reference). B, Atrial pacing demonstrates decremental AV conduction with a constant HV interval of 30 ms. C, Schematic illustrations of cardiac conduction in the absence or presence of fasciculoventricular connections. Left, During sinus rhythm, atrial activation in the normal heart proceeds over AV node, the His bundle, and bundle branches to ventricles so that the earliest ventricular activation occurs in the apical portion. Right, Atrial activation in the presence of a fasciculoventricular pathway proceeds through AV node to the His bundle and downward over the fasciculoventricular bypass tract as well as the distal portion of the His bundle and bundle branches to ventricles so that early ventricular activation in the basal portion of the right ventricle occurs with a short HV interval and a manifestation of ventricular preexcitation. D, Left, Midventricular pacing in the normal heart results in a right bundle (RB)-H activation sequence consistent with ventricular activation through the right bundle to the His bundle. Right, Midventricular pacing in the presence of retrograde fasciculoventricular pathway conduction causes a reversed H-RB activation sequence consistent with ventricular activation through the fasciculoventricular bypass tract to the His bundle. E, Tracings obtained from electrophysiological study in patient 2. Atrial pacing demonstrates decremental AV conduction with a constant HV interval of 22 ms. Note that earlier ventricular activation of the proximal than the distal site of the His bundle is seen (a long-dotted line used as reference). F, Prolongation of PR intervals with no change in the degree of ventricular preexcitation and HV intervals until progression to complete AV block during adenosine administration. A indicates atrial wave; AV, atrioventricular; AVN, atrioventricular node; FV, fasciculoventricular pathway; H, His bundle; HV, His-ventricular; LBB, left bundle branch; P, P wave; RBB, right bundle branch; SR, sinus rhythm; and VA, ventriculoatrial.In patient 2, the baseline HV intervals measured 22 ms during sinus rhythm. With programmed atrial stimulation, AV conduction was decremental with evidence of dual AV node physiology, but the HV intervals and degree of ventricular preexcitation remained constant (Figure [E]); local ventricular activation recorded from the proximal site of the His bundle was earlier than the distal His bundle and preceded the onset of surface delta waves by 15 ms (Figure [E]). These findings were also compatible with electrophysiological characteristics of an FV pathway.In both patients, adenosine challenge resulted in the prolongation of PR intervals with no change in the degree of ventricular preexcitation on surface ECG or HV intervals until progression to complete AV block (Figure [F]). No arrhythmias were inducible either with programmed extrastimulation or with burst pacing from both the coronary sinus and right ventricular apex. In the patient 3, despite no electrophysiological assessment performed, the presence of intermittent AV block indicated that the electrocardiographic preexcitation was because of an infranodal bypass tract consistent with an FV pathway (Figure in the Data Supplement).The underlying mechanism for the formation of FV connections is unknown but possible because of the disruption of the His bundle insulation, which was raised by the fact that the earliest ventricular activation was recorded at the His bundle region in our study. Anatomically, the His bundle is covered with a thin layer of myocardial fibers or courses directly within interventricular muscle in 79% of human hearts.4 When the fibrous sheath, which normally insulates the His bundle from superficial myocardial fibers, is disrupted by excessive accumulation of glycogen granules and autophagic materials, direct electrical connections from the His bundle to adjacent ventricular myocardium occur and lead to an acquired form of ventricular preexcitation. A similar mechanism was previously verified in a transgenic mouse overexpressing mutant PRKAG2, which resulted in glycogen storage cardiomyopathy and preexcitation findings.5 Cardiac histopathology revealed that the annulus fibrosis was disrupted by glycogen-filled myocytes.In summary, our study proved that ventricular preexcitation in patients with Danon disease was because of the presence of FV pathways characterized by bidirectional conduction and take-off from the proximal His bundle. The underlying mechanism for the formation of FV pathways warrants further study.AcknowledgmentsWe thank the patients who volunteered to participate in the study.Sources of FundingDr Liu receives research grants from the National Natural Science Foundation of China (NSFC-81400259) and Guangdong Province (2014A030310470). Dr Wu receives research grants from the Science and Technology Programs of Guangdong Province (no. 2014B070705005) and Guangzhou City (no. 201508020261).DisclosuresDr Liu receives an educational fee from Boston Scientific. The other authors report no conflicts.FootnotesThe Data Supplement is available with this article at https://www.ahajournals.org/doi/suppl/10.1161/CIRCEP.118.006704.https://www.ahajournals.org/journal/circep*Drs Liu, F. Wang, and Chen contributed equally to this work as first authors.Shulin Wu, MD, Guangdong Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, 106 Zhongshan Er Rd, Guangzhou 510080, China. Email [email protected]comReferences1. Yamada T, Shimojo S, Koori T, Mora M, Riggs JE, Oh SJ, Koga Y, Sue CM, Yamamoto A, Murakami N, Shanske S, Byrne E, Bonilla E, Nonaka I, DiMauro S, Hirano M. Primary lamp-2 deficiency causes x-linked vacuolar cardiomyopathy and myopathy (Danon disease).Nature. 2000; 406:906–910.CrossrefMedlineGoogle Scholar2. Danon MJ, Oh SJ, DiMauro S, Manaligod JR, Eastwood A, Naidu S, Schliselfeld LH. Lysosomal glycogen storage disease with normal acid maltase.Neurology. 1981; 31:51–57.CrossrefMedlineGoogle Scholar3. Boucek D, Jirikowic J, Taylor M. Natural history ofDanon disease.Genet Med. 2011; 13:563–568. doi: 10.1097/GIM.0b013e31820ad795CrossrefMedlineGoogle Scholar4. Kawashima T, Sasaki H. A macroscopic anatomical investigation of atrioventricular bundle locational variation relative to the membranous part of the ventricular septum in elderly human hearts.Surg Radiol Anat. 2005; 27:206–213. doi: 10.1007/s00276-004-0302-7CrossrefMedlineGoogle Scholar5. Arad M, Moskowitz IP, Patel VV, Ahmad F, Perez-Atayde AR, Sawyer DB, Walter M, Li GH, Burgon PG, Maguire CT, Stapleton D, Schmitt JP, Guo XX, Pizard A, Kupershmidt S, Roden DM, Berul CI, Seidman CE, Seidman JG. Transgenic mice overexpressing mutant PRKAG2 define the cause of Wolff-Parkinson-White syndrome in glycogen storage cardiomyopathy.Circulation. 2003; 107:2850–2856. doi: 10.1161/01.CIR.0000075270.13497.2BLinkGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetailsCited By Wang Y, Jia M, Guo Y, Zhang T and Ning B (2022) Case Report: Danon Disease: Six Family Members and Literature Review, Frontiers in Cardiovascular Medicine, 10.3389/fcvm.2022.842282, 9 Argirò A, Ho C, Day S, van der Velden J, Cerbai E, Saberi S, Tardiff J, Lakdawala N and Olivotto I (2022) Sex‐Related Differences in Genetic Cardiomyopathies, Journal of the American Heart Association, 11:9, Online publication date: 3-May-2022. Chen X, Fu L, He J, Bai R, Zeng S, Liao H, Deng H, Xue Y, Wu S and Liu Y (2022) A Frequent Observation of Wolff-Parkinson-White Syndrome and Fasciculoventricular Pathways in Patients With Danon Disease, Circulation Journal, 10.1253/circj.CJ-21-0572, 86:2, (309-318), Online publication date: 25-Jan-2022. Chen X, Li H, Liao H, Zhan X, Zhong Z, Zhang Q, Liu L, Liang Y, Deng H, Fang X, Xue Y, Wu S and Liu Y (2021) Clinical and genetic spectrum in Chinese families with Fabry disease: a single‐centre case series, ESC Heart Failure, 10.1002/ehf2.13638, 8:6, (5436-5444), Online publication date: 1-Dec-2021. Zhai Y, Miao J, Peng Y, Wang Y, Dong J and Zhao X (2021) Clinical features of Danon disease and insights gained from LAMP-2 deficiency models, Trends in Cardiovascular Medicine, 10.1016/j.tcm.2021.10.012, Online publication date: 1-Nov-2021. Darden D, Hsu J, Tzou W, von Alvensleben J, Brooks M, Hoffmayer K, Brambatti M, Sauer W, Feld G and Adler E (2021) Fasciculoventricular and atrioventricular accessory pathways in patients with Danon disease and preexcitation: A multicenter experience, Heart Rhythm, 10.1016/j.hrthm.2021.03.024, 18:7, (1194-1202), Online publication date: 1-Jul-2021. Gu W, Maimaitijiang A, Huang Q, Wu B, Sun S, Luo X, Li J and Xiong N (2021) Pseudo normalization of H–V interval due to intra-His block in a patient with fasciculoventricular accessory pathway, Journal of Electrocardiology, 10.1016/j.jelectrocard.2020.11.010, 64, (9-11), Online publication date: 1-Jan-2021. Lotan D, Salazar-Mendiguchía J, Mogensen J, Rathore F, Anastasakis A, Kaski J, Garcia-Pavia P, Olivotto I, Charron P, Biagini E, Baban A, Limongelli G, Ashram W, Wasserstrum Y, Galvin J, Zorio E, Iacovoni A, Monserrat L, Spirito P, Iascone M, Arad M, Mandel C, Morillas H, Gonzalez-Lopez E, Dominguez F, Marchetti D, Pezzoli L, Anne Walsh K, McGorrian C, Ditaranto R, Vitale G, Villard E, Richard P, Monda E, Caiazza M, Passantino S, Girolami F, Drago F, Adorisio R, Field E, Freimark D and Baandrup U (2020) Clinical Profile of Cardiac Involvement in Danon Disease, Circulation: Genomic and Precision Medicine, 13:6, Online publication date: 1-Dec-2020. Montañés M, Granados M, Valverde M, Palomino J, Fontenla A and Escribano L (2020) Wolff Parkinson white pattern in Danon disease: When preexcitation is not what it seems, Journal of Electrocardiology, 10.1016/j.jelectrocard.2020.08.020, 62, (161-164), Online publication date: 1-Sep-2020. Cenacchi G, Papa V, Pegoraro V, Marozzo R, Fanin M and Angelini C (2019) Review: Danon disease: Review of natural history and recent advances, Neuropathology and Applied Neurobiology, 10.1111/nan.12587, 46:4, (303-322), Online publication date: 1-Jun-2020. Hoffmayer K, Han F, Singh D and Scheinman M (2020) Variants of accessory pathways, Pacing and Clinical Electrophysiology, 10.1111/pace.13830, 43:1, (21-29), Online publication date: 1-Jan-2020. Zhang Y, Ren H and Zhou S (2020) A case report of delayed diagnosis of danon disease, Medicine, 10.1097/MD.0000000000022640, 99:40, (e22640) Soares Correa F, Lokhandwala Y, Sánchez‐Quintana D, Mori S, Anderson R, Wellens H and Back Sternick E (2019) Unusual variants of pre‐excitation: From anatomy to ablation: Part III—Clinical presentation, electrophysiologic characteristics, when and how to ablate nodoventricular, nodofascicular, fasciculoventricular pathways, along with considerations of permanent junctional reciprocating tachycardia, Journal of Cardiovascular Electrophysiology, 10.1111/jce.14247, 30:12, (3097-3115), Online publication date: 1-Dec-2019. Jhaveri S, Herber J, Zahka K, Boyle G, Saarel E and Aziz P (2019) Arrhythmias and fasciculoventricular pathways in patients with Danon disease: A single center experience, Journal of Cardiovascular Electrophysiology, 10.1111/jce.14049, 30:10, (1932-1938), Online publication date: 1-Oct-2019. Guo S, Zhou L, Wang R, Lv Z, Xu H, Han B, Korantzopoulos P, Hu F and Liu T (2019) Danon disease: Two patients with atrial fibrillation in a single family and review of the literature, Experimental and Therapeutic Medicine, 10.3892/etm.2019.7777 Liu Y, Chen X, Wang F, Liang Y, Deng H, Liao H, Zhang Q, Zhang B, Zhan X, Fang X, Shehata M, Wang X, Xue Y and Wu S (2019) Prevalence and clinical characteristics of Danon disease among patients with left ventricular hypertrophy and concomitant electrocardiographic preexcitation, Molecular Genetics & Genomic Medicine, 10.1002/mgg3.638, 7:5, (e638), Online publication date: 1-May-2019. September 2018Vol 11, Issue 9 Advertisement Article InformationMetrics © 2018 American Heart Association, Inc.https://doi.org/10.1161/CIRCEP.118.006704PMID: 30354295 Originally publishedSeptember 13, 2018 Keywordslysosomal-associated membrane protein 2heart ventriclesbundle of Hishypertrophy, left ventriculargenetic testingPDF download Advertisement SubjectsCardiomyopathyElectrophysiologyGeneticsPrecision Medicine